PT3430043T - Anticorpos anti-tnfalfa e respectivos fragmentos funcionais - Google Patents

Anticorpos anti-tnfalfa e respectivos fragmentos funcionais

Info

Publication number: PT3430043T
Authority: PT; Portugal
Prior art keywords: tnfalpha; antibodies; functional fragments; fragments; functional
Prior art date: 2016-03-17

Application number

PT177107489T

Other languages

English (en)

Original Assignee

Tillotts Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2017-03-16

Publication date

2023-11-23

2017-03-16 Application filed by Tillotts Pharma Ag filed Critical Tillotts Pharma Ag

2023-11-23 Publication of PT3430043T publication Critical patent/PT3430043T/pt

Links

239000012634 fragment Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT177107489T 2016-03-17 2017-03-16 Anticorpos anti-tnfalfa e respectivos fragmentos funcionais PT3430043T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP16160907.8A EP3219726B1 (en)	2016-03-17	2016-03-17	Anti-tnf alpha-antibodies and functional fragments thereof

Publications (1)

Publication Number	Publication Date
PT3430043T true PT3430043T (pt)	2023-11-23

Family

ID=55542576

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT161609078T PT3219726T (pt)	2016-03-17	2016-03-17	Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos
PT177107489T PT3430043T (pt)	2016-03-17	2017-03-16	Anticorpos anti-tnfalfa e respectivos fragmentos funcionais

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PT161609078T PT3219726T (pt)	2016-03-17	2016-03-17	Alfa-anticorpos anti-tnf e fragmentos funcionais dos mesmos

Country Status (39)

Country	Link
US (3)	US11459383B2 (pt)
EP (3)	EP3219726B1 (pt)
JP (2)	JP7129398B2 (pt)
KR (2)	KR102470235B1 (pt)
CN (1)	CN109071650B (pt)
AR (1)	AR107917A1 (pt)
AU (1)	AU2017235387A1 (pt)
BR (1)	BR112018016667A2 (pt)
CA (1)	CA3011784C (pt)
CL (1)	CL2018002649A1 (pt)
CO (1)	CO2018009783A2 (pt)
CR (1)	CR20180448A (pt)
CY (1)	CY1123784T1 (pt)
DK (2)	DK3219726T3 (pt)
EA (1)	EA039760B1 (pt)
ES (2)	ES2836349T3 (pt)
FI (1)	FI3430043T3 (pt)
GE (1)	GEP20217307B (pt)
HR (2)	HRP20231464T1 (pt)
HU (2)	HUE052773T2 (pt)
IL (1)	IL261031A (pt)
JO (2)	JOP20170064B1 (pt)
LT (2)	LT3219726T (pt)
MA (1)	MA43717B1 (pt)
MD (1)	MD3430043T2 (pt)
MX (1)	MX2018011258A (pt)
MY (1)	MY194041A (pt)
PH (1)	PH12018501907A1 (pt)
PL (2)	PL3219726T3 (pt)
PT (2)	PT3219726T (pt)
RS (2)	RS61374B1 (pt)
SA (1)	SA518400027B1 (pt)
SG (1)	SG11201807062RA (pt)
SI (2)	SI3219726T1 (pt)
TN (1)	TN2018000298A1 (pt)
TW (2)	TWI829444B (pt)
UY (1)	UY37157A (pt)
WO (1)	WO2017158092A1 (pt)
ZA (4)	ZA202108602B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2017158079A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	Anti-tnfalpha-antibodies and functional fragments thereof
CN109071649B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
ES2836349T3 (es) *	2016-03-17	2021-06-24	Tillotts Pharma Ag	Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos
SI3219727T1 (sl)	2016-03-17	2021-04-30	Tillotts Pharma Ag	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
EP3456737B1 (en) *	2017-09-19	2024-02-14	Tillotts Pharma Ag	Antibody variants
RS61883B1 (sr) *	2017-09-19	2021-06-30	Tillotts Pharma Ag	Varijante antitela
WO2020114616A1 (en)	2018-12-07	2020-06-11	Tillotts Pharma Ag	Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4444887A (en)	1979-12-10	1984-04-24	Sloan-Kettering Institute	Process for making human antibody producing B-lymphocytes
US4716111A (en)	1982-08-11	1987-12-29	Trustees Of Boston University	Process for producing human antibodies
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en)	1984-09-03	1984-10-10	Neuberger M S	Chimeric proteins
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
GB8720833D0 (en)	1987-09-04	1987-10-14	Celltech Ltd	Recombinant dna product
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
GB8907617D0 (en)	1989-04-05	1989-05-17	Celltech Ltd	Drug delivery system
US5413923A (en)	1989-07-25	1995-05-09	Cell Genesys, Inc.	Homologous recombination for universal donor cells and chimeric mammalian hosts
GB8928874D0 (en)	1989-12-21	1990-02-28	Celltech Ltd	Humanised antibodies
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
US5814318A (en)	1990-08-29	1998-09-29	Genpharm International Inc.	Transgenic non-human animals for producing heterologous antibodies
US5661016A (en)	1990-08-29	1997-08-26	Genpharm International Inc.	Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DK0546073T3 (da)	1990-08-29	1998-02-02	Genpharm Int	Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en)	1990-08-29	1996-08-13	Genpharm International, Inc.	Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en)	1990-08-29	1997-05-27	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en)	1990-08-29	1997-04-29	Genpharm International, Inc.	Transgenic non-human animals for producing heterologous antibodies
GB9109645D0 (en)	1991-05-03	1991-06-26	Celltech Ltd	Recombinant antibodies
US5919452A (en)	1991-03-18	1999-07-06	New York University	Methods of treating TNFα-mediated disease using chimeric anti-TNF antibodies
EP0519596B1 (en)	1991-05-17	2005-02-23	Merck & Co. Inc.	A method for reducing the immunogenicity of antibody variable domains
IE922437A1 (en)	1991-07-25	1993-01-27	Idec Pharma Corp	Recombinant antibodies for human therapy
US5565332A (en)	1991-09-23	1996-10-15	Medical Research Council	Production of chimeric antibodies - a combinatorial approach
ES2227512T3 (es)	1991-12-02	2005-04-01	Medical Research Council	Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
NO309690B1 (no)	1995-01-23	2001-03-12	Western Atlas Int Inc	Detonasjonsanordning av type eksploderende brotråd for bruk med et perforeringsverktöy i en brönn
EP0822830B1 (en)	1995-04-27	2008-04-02	Amgen Fremont Inc.	Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en)	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
MX336813B (es) *	1996-02-09	2016-02-02	Abbvie Biotechnology Ltd	Anticuerpos humanos que ligan el tnfa humano.
US5916771A (en)	1996-10-11	1999-06-29	Abgenix, Inc.	Production of a multimeric protein by cell fusion method
ES2301183T3 (es)	1996-12-03	2008-06-16	Amgen Fremont Inc.	Anticuerpo completamente humano que se une al receptor del egfr.
GB9625640D0 (en)	1996-12-10	1997-01-29	Celltech Therapeutics Ltd	Biological products
RU2224766C2 (ru)	1997-04-14	2004-02-27	Микромет Аг	Способ получения рецепторов для человеческих антигенов и их применение
US6235883B1 (en)	1997-05-05	2001-05-22	Abgenix, Inc.	Human monoclonal antibodies to epidermal growth factor receptor
ATE384792T1 (de)	1998-11-18	2008-02-15	Genentech Inc	Antikörpervarianten mit höheren bindungsaffinitäten im vergleich zu parentalen antikörpern
GB0412181D0 (en)	2004-06-01	2004-06-30	Celltech R&D Ltd	Biological products
US7431927B2 (en)	2005-03-24	2008-10-07	Epitomics, Inc.	TNFα-neutralizing antibodies
PT2390267E (pt)	2005-06-07	2013-07-16	Esbatech A Novartis Co Llc	Anticorpos estáveis e solúveis que inibem tnf(alfa)
CN107936117B (zh)	2008-06-25	2022-12-23	诺华股份有限公司	抑制TNFα的稳定和可溶的抗体
HUE038432T2 (hu)	2008-06-25	2018-10-29	Esbatech Alcon Biomed Res Unit	Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
WO2010003268A2 (en)	2008-07-10	2010-01-14	Esbatech, An Alcon Biomedical Research Unit Llc	Methods and compositions for enhanced delivery of macromolecules
JP2013523153A (ja) *	2010-04-07	2013-06-17	アッヴィ・インコーポレイテッド	ＴＮＦ−α結合タンパク質
AU2011277983C1 (en)	2010-07-16	2016-09-29	Ablynx Nv	Modified single domain antigen binding molecules and uses thereof
BR112013007501B1 (pt) *	2010-09-30	2022-04-19	Chengdu Kanghong Biotechnologies Co., Ltd.	Anticorpo humanizado anti-fator de necrose tumoral a, ou um fragmento de ligação ao antígeno do mesmo, uso e composição farmacêutica
CA2914829A1 (en)	2013-06-26	2014-12-31	Numab Ag	Novel antibody frameworks
CA2924520C (en) *	2013-11-01	2023-09-26	Ibc Pharmaceuticals, Inc.	Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
CN106414498B (zh) *	2014-03-26	2020-09-08	细胞药物瑞士股份公司	TNF α的结合成员
SI3219727T1 (sl)	2016-03-17	2021-04-30	Tillotts Pharma Ag	Anti-TNF alfa protitelesa in njihovi funkcionalni fragmenti
CN109071649B (zh)	2016-03-17	2021-10-01	努玛创新有限公司	抗TNFα抗体及其功能片段
WO2017158079A1 (en)	2016-03-17	2017-09-21	Numab Innovation Ag	Anti-tnfalpha-antibodies and functional fragments thereof
ES2836349T3 (es) *	2016-03-17	2021-06-24	Tillotts Pharma Ag	Anticuerpos anti-TNF-alfa y fragmentos funcionales de los mismos

2016
- 2016-03-17 ES ES16160907T patent/ES2836349T3/es active Active
- 2016-03-17 LT LTEP16160907.8T patent/LT3219726T/lt unknown
- 2016-03-17 SI SI201631040T patent/SI3219726T1/sl unknown
- 2016-03-17 DK DK16160907.8T patent/DK3219726T3/da active
- 2016-03-17 RS RS20210112A patent/RS61374B1/sr unknown
- 2016-03-17 PT PT161609078T patent/PT3219726T/pt unknown
- 2016-03-17 EP EP16160907.8A patent/EP3219726B1/en active Active
- 2016-03-17 HU HUE16160907A patent/HUE052773T2/hu unknown
- 2016-03-17 PL PL16160907T patent/PL3219726T3/pl unknown
2017
- 2017-03-16 PL PL17710748.9T patent/PL3430043T3/pl unknown
- 2017-03-16 JO JOP/2017/0064A patent/JOP20170064B1/ar active
- 2017-03-16 AU AU2017235387A patent/AU2017235387A1/en active Pending
- 2017-03-16 DK DK17710748.9T patent/DK3430043T3/da active
- 2017-03-16 TN TNP/2018/000298A patent/TN2018000298A1/en unknown
- 2017-03-16 US US16/085,506 patent/US11459383B2/en active Active
- 2017-03-16 EP EP23192170.1A patent/EP4275745A3/en active Pending
- 2017-03-16 EA EA201891788A patent/EA039760B1/ru unknown
- 2017-03-16 CA CA3011784A patent/CA3011784C/en active Active
- 2017-03-16 WO PCT/EP2017/056237 patent/WO2017158092A1/en active Application Filing
- 2017-03-16 KR KR1020187022632A patent/KR102470235B1/ko active IP Right Grant
- 2017-03-16 SI SI201731446T patent/SI3430043T1/sl unknown
- 2017-03-16 ES ES17710748T patent/ES2963221T3/es active Active
- 2017-03-16 MD MDE20190099T patent/MD3430043T2/ro unknown
- 2017-03-16 HR HRP20231464TT patent/HRP20231464T1/hr unknown
- 2017-03-16 FI FIEP17710748.9T patent/FI3430043T3/fi active
- 2017-03-16 MA MA43717A patent/MA43717B1/fr unknown
- 2017-03-16 GE GEAP201714876A patent/GEP20217307B/en unknown
- 2017-03-16 JP JP2019500013A patent/JP7129398B2/ja active Active
- 2017-03-16 LT LTEPPCT/EP2017/056237T patent/LT3430043T/lt unknown
- 2017-03-16 CR CR20180448A patent/CR20180448A/es unknown
- 2017-03-16 EP EP17710748.9A patent/EP3430043B1/en active Active
- 2017-03-16 SG SG11201807062RA patent/SG11201807062RA/en unknown
- 2017-03-16 KR KR1020227040533A patent/KR20220158877A/ko not_active Application Discontinuation
- 2017-03-16 PT PT177107489T patent/PT3430043T/pt unknown
- 2017-03-16 BR BR112018016667A patent/BR112018016667A2/pt unknown
- 2017-03-16 HU HUE17710748A patent/HUE064238T2/hu unknown
- 2017-03-16 MX MX2018011258A patent/MX2018011258A/es unknown
- 2017-03-16 CN CN201780015298.5A patent/CN109071650B/zh active Active
- 2017-03-16 RS RS20231087A patent/RS64830B1/sr unknown
- 2017-03-16 MY MYPI2018001566A patent/MY194041A/en unknown
- 2017-03-17 TW TW111145252A patent/TWI829444B/zh active
- 2017-03-17 UY UY0001037157A patent/UY37157A/es not_active Application Discontinuation
- 2017-03-17 AR ARP170100675A patent/AR107917A1/es unknown
- 2017-03-17 TW TW106108832A patent/TWI784945B/zh active
2018
- 2018-08-07 IL IL261031A patent/IL261031A/en unknown
- 2018-09-06 PH PH12018501907A patent/PH12018501907A1/en unknown
- 2018-09-14 CL CL2018002649A patent/CL2018002649A1/es unknown
- 2018-09-16 SA SA518400027A patent/SA518400027B1/ar unknown
- 2018-09-17 CO CONC2018/0009783A patent/CO2018009783A2/es unknown
2021
- 2021-01-13 CY CY20211100021T patent/CY1123784T1/el unknown
- 2021-01-22 HR HRP20210123TT patent/HRP20210123T1/hr unknown
- 2021-04-22 JO JOP/2021/0085A patent/JOP20210085A1/ar unknown
- 2021-11-04 ZA ZA2021/08602A patent/ZA202108602B/en unknown
- 2021-11-04 ZA ZA2021/08599A patent/ZA202108599B/en unknown
- 2021-11-04 ZA ZA2021/08601A patent/ZA202108601B/en unknown
- 2021-11-04 ZA ZA2021/08600A patent/ZA202108600B/en unknown
2022
- 2022-06-06 JP JP2022091271A patent/JP2022130407A/ja active Pending
- 2022-08-18 US US17/890,857 patent/US20230272059A1/en active Pending
- 2022-10-03 US US17/958,759 patent/US20230279091A1/en active Pending

Also Published As

Publication number	Publication date
MA43717B1 (fr)	2023-11-30
CN109071650B (zh)	2022-05-13
KR20180120149A (ko)	2018-11-05
JP2022130407A (ja)	2022-09-06
HRP20231464T1 (hr)	2024-03-01
TN2018000298A1 (en)	2020-01-16
US20210198353A1 (en)	2021-07-01
TW201739766A (zh)	2017-11-16
FI3430043T3 (fi)	2023-11-17
HUE064238T2 (hu)	2024-02-28
US20230272059A1 (en)	2023-08-31
ZA202108601B (en)	2022-03-30
HRP20210123T1 (hr)	2021-03-05
SA518400027B1 (ar)	2022-03-06
JP7129398B2 (ja)	2022-09-01
CA3011784A1 (en)	2017-09-21
ZA202108599B (en)	2022-03-30
RS61374B1 (sr)	2021-02-26
AR107917A1 (es)	2018-06-28
EP4275745A2 (en)	2023-11-15
ES2836349T3 (es)	2021-06-24
ES2963221T3 (es)	2024-03-26
EP3430043B1 (en)	2023-08-30
TWI829444B (zh)	2024-01-11
KR102470235B1 (ko)	2022-11-24
EP4275745A3 (en)	2023-12-20
ZA202108600B (en)	2022-03-30
HUE052773T2 (hu)	2021-05-28
JOP20210085A1 (ar)	2023-01-30
MA43717A (fr)	2018-11-28
CO2018009783A2 (es)	2018-09-28
WO2017158092A1 (en)	2017-09-21
CL2018002649A1 (es)	2018-11-09
EA039760B1 (ru)	2022-03-10
ZA202108602B (en)	2022-03-30
PL3219726T3 (pl)	2021-07-19
LT3219726T (lt)	2021-01-25
BR112018016667A2 (pt)	2019-02-05
UY37157A (es)	2017-10-31
CA3011784C (en)	2024-04-23
JP2019512268A (ja)	2019-05-16
TW202311288A (zh)	2023-03-16
IL261031A (en)	2018-10-31
MX2018011258A (es)	2019-02-13
JOP20170064B1 (ar)	2021-08-17
PT3219726T (pt)	2020-12-15
CR20180448A (es)	2019-01-25
SG11201807062RA (en)	2018-09-27
EA201891788A1 (ru)	2019-01-31
EP3219726B1 (en)	2020-12-02
MD3430043T2 (ro)	2024-02-29
GEP20217307B (en)	2021-10-25
DK3219726T3 (da)	2020-12-07
SI3219726T1 (sl)	2021-02-26
SI3430043T1 (sl)	2024-01-31
EP3219726A1 (en)	2017-09-20
KR20220158877A (ko)	2022-12-01
PL3430043T3 (pl)	2024-03-11
CY1123784T1 (el)	2022-05-27
AU2017235387A1 (en)	2018-09-27
TWI784945B (zh)	2022-12-01
MY194041A (en)	2022-11-09
US11459383B2 (en)	2022-10-04
LT3430043T (lt)	2023-12-27
EP3430043A1 (en)	2019-01-23
CN109071650A (zh)	2018-12-21
RS64830B1 (sr)	2023-12-29
PH12018501907A1 (en)	2019-06-17
DK3430043T3 (da)	2023-11-27
US20230279091A1 (en)	2023-09-07

Publication	Publication Date	Title
HK1254953A1 (zh)	2019-08-02	抗vista抗體和片段
HK1251183A1 (zh)	2019-01-25	生物綴合物及其用途
IL261140A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
ZA202108601B (en)	2022-03-30	Anti-tnfalpha-antibodies and functional fragments thereof
IL261261A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
IL261098A (en)	2018-10-31	Antibodies against tnf-alpha and functional fragments thereof
HK1247122A1 (zh)	2018-09-21	組合及其用途
IL254241A0 (en)	2017-10-31	Etv2 and its uses
IL261793A (en)	2018-10-31	Anti-tnfalpha antibodies and their functional parts
IL264473A (en)	2019-02-28	GPR156 variants and their uses
AU2017235061A1 (en)	2017-09-21	Anti-TNFalpha-antibodies and functional fragments thereof
GB201707279D0 (en)	2017-06-21	Multiearphones and polyearphones
GB2545167B (en)	2022-02-16	Cloches and use thereof
GB201617925D0 (en)	2016-12-07	Proteins and uses
GB201500278D0 (en)	2015-02-25	Novel combination and use